The university filed a lawsuit against BioNTech four months ago, claiming that the company licensed vaccine technology ...
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $145.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback